Adial Pharmaceuticals receives Nasdaq delisting notice for equity below $2.5M minimum

ADIAL PHARMACEUTICALS, INC.

Stockholders' equity of $2,126,662 as of March 31, 2025, below Nasdaq's $2.5M requirement.
Company has 45 calendar days (until July 7, 2025) to submit a compliance plan to Nasdaq.
If plan accepted, Nasdaq may grant up to 180 days extension to regain compliance.
Failure to regain compliance could lead to delisting; company may request a hearing.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.